Plain-English translation of NCT04424719 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
The SALOME study is designed to monitor patients with uveal melanoma (a type of eye cancer) who are at high risk of their cancer coming back. Patients will receive regular MRI scans of the liver and blood tests over several years to catch any signs of recurrence as early as possible. This research aims to find the best way to follow these patients and potentially identify early warning signs through blood biomarkers.
Eye melanoma can spread to other parts of the body, especially the liver, even years after the original tumor is treated. This study exists to figure out the most effective schedule for monitoring high-risk patients and to develop better blood tests that might detect cancer recurrence before it becomes visible on imaging.
You likely qualify if…
You likely don't qualify if…
You will visit the specialist center for medical oncology at the start and then every 6 months for imaging (liver MRI scans). If your eye was removed, you'll also provide small blood samples at the same intervals to help researchers study early warning signs. This follow-up will continue for at least 5 years, with the possibility of extending to 10 years, and additional visits may occur if you develop metastatic disease or need treatment adjustments.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
France
Sponsor
Institut Curie
Enrollment target
~700 participants
Started
July 2020
Primary completion
July 2037
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sophie Piperno-Neumann, MD
Institut Curie
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.